BRPI0509026A - formulação de aerossol, método para a prevenção e tratamento de infecção causada por bactéria do trato respiratório, e, solução - Google Patents

formulação de aerossol, método para a prevenção e tratamento de infecção causada por bactéria do trato respiratório, e, solução

Info

Publication number
BRPI0509026A
BRPI0509026A BRPI0509026-1A BRPI0509026A BRPI0509026A BR PI0509026 A BRPI0509026 A BR PI0509026A BR PI0509026 A BRPI0509026 A BR PI0509026A BR PI0509026 A BRPI0509026 A BR PI0509026A
Authority
BR
Brazil
Prior art keywords
phosphomycin
tobramycin
prevention
treatment
formulation
Prior art date
Application number
BRPI0509026-1A
Other languages
English (en)
Inventor
William R Baker
David L Macleod
Original Assignee
Corus Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corus Pharma Inc filed Critical Corus Pharma Inc
Publication of BRPI0509026A publication Critical patent/BRPI0509026A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
    • A61M11/005—Sprayers or atomisers specially adapted for therapeutic purposes using ultrasonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
    • B65D85/00—Containers, packaging elements or packages, specially adapted for particular articles or materials
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
    • Y10T436/107497—Preparation composition [e.g., lysing or precipitation, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Dispersion Chemistry (AREA)
  • Mechanical Engineering (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

FORMULAçãO DE ABROSSOL, MéTODO PARA A PREVENçãO E TRATAMENTO DE INFECçãO CAUSADA POR BACTéRIA DO TRATO RESPIRATóRIO, E, SOLUçãO é descrita uma formulação de combinação de fosfomicina mais tobramicina, para administração por aerossolização. A formulação de combinação de fosfomicina e tobramicina, contendo uma quantidade eficaz de fosfomicina mais tobramicina, é capaz de inibir bactérias susceptíveis. A fosfomicina e tobramicina são formuladas separadamente em uma ampola dupla, de modo que, quando reconstituídas, o pH situa-se entre 4,5 e 8,0, ou como um pó seco. Método de tratamento de infecções do trato respiratório por uma formulação suprida como um aerossol, tendo diâmetro médio de massa predominantemente entre 1 a 5 produzida por um nebulizador a jato ou ultrassónico (ou equivalente) ou inalador de pó seco.
BRPI0509026-1A 2004-05-17 2005-05-02 formulação de aerossol, método para a prevenção e tratamento de infecção causada por bactéria do trato respiratório, e, solução BRPI0509026A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US57173904P 2004-05-17 2004-05-17
US65900505P 2005-03-03 2005-03-03
PCT/US2005/014690 WO2005110022A2 (en) 2004-05-17 2005-05-02 Aerosolized fosfomycin/aminoglycoside combination for the treatment of bacterial respiratory infections

Publications (1)

Publication Number Publication Date
BRPI0509026A true BRPI0509026A (pt) 2007-09-18

Family

ID=35394588

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0509026-1A BRPI0509026A (pt) 2004-05-17 2005-05-02 formulação de aerossol, método para a prevenção e tratamento de infecção causada por bactéria do trato respiratório, e, solução

Country Status (18)

Country Link
US (4) US7943118B2 (pt)
EP (3) EP2316419B1 (pt)
JP (1) JP4745340B2 (pt)
AR (1) AR048793A1 (pt)
AT (1) ATE493969T1 (pt)
AU (2) AU2005244153B2 (pt)
BR (1) BRPI0509026A (pt)
CA (1) CA2564546C (pt)
CY (3) CY1112004T1 (pt)
DE (1) DE602005025754D1 (pt)
DK (3) DK2266534T3 (pt)
ES (3) ES2392389T3 (pt)
IL (2) IL179277A (pt)
PL (3) PL2316419T3 (pt)
PT (3) PT1750667E (pt)
SI (3) SI2266534T1 (pt)
TW (1) TWI409074B (pt)
WO (1) WO2005110022A2 (pt)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3741866A1 (en) * 2019-05-20 2020-11-25 Liofilchem S.r.l. Kit and method for antibiotics susceptibility testing with the agar dilution method

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2316419B1 (en) 2004-05-17 2012-07-11 Gilead Sciences, Inc. Aerosolized fosfomycin/tobramycin combination for the treatment of bacterial respiratory infections
US20060210483A1 (en) * 2005-03-02 2006-09-21 Kodsi Robert E Non-systemic antibiotic formulations and related method of use and treatment of upper respiratory infections
US20100093650A1 (en) * 2006-10-11 2010-04-15 Laboratories Smb S.A. Pharmaceutical Anit-Infective Composition for Inhalation
EP2101787B1 (en) * 2006-12-11 2013-09-18 Drugrecure ApS Methods for treating cystic fibrosis or pneumonia with bacterial infection via pulmonary administration of fosfomycin
EP2018864A1 (en) 2007-07-23 2009-01-28 Biomet Deutschland GmbH Pharmaceutical composition, substrate comprising a pharmaceutical composition, and use of a pharmaceutical composition
DE102008046610A1 (de) * 2008-09-09 2010-03-11 Biomet Deutschland Gmbh Verwendung einer pharmazeutischen Zusammensetzung zur lokalen Infektionstherapie sowie Medizinprodukt
CA2741306A1 (en) * 2008-10-21 2010-04-29 Gilead Sciences, Inc. Fosfomycin/tobramycin combinations for the treatment and prevention of ophthalmic, otological and dermatological infections
EP2504013A1 (en) 2009-11-24 2012-10-03 Gilead Sciences, Inc. Inhaled fosfomycin/tobramycin for the treatment of chronic obstructive pulmonary disease
CA2784033A1 (en) * 2009-12-22 2011-07-21 Kalobios Pharmaceuticals, Inc. A method of treating a staphylococcus infection in a patient having a low-level pathogenic pseudomonas aeruginosa infection
US20130164351A1 (en) * 2010-08-30 2013-06-27 Cempra Pharmaceuticals Inc. Methods of treating bacterial infections through pulmonary delivery of fusidic acid
WO2012154483A1 (en) 2011-05-06 2012-11-15 Gilead Sciences, Inc. Dry powder fosfomycin/tobramycin formulation for inhalation
US9572774B2 (en) 2011-05-19 2017-02-21 Savara Inc. Dry powder vancomycin compositions and associated methods
US8826904B2 (en) 2011-07-12 2014-09-09 Cardeas Pharma Corporation Formulations of aminoglycoside and fosfomycin combinations and methods and systems for treatment of ventilator associated pneumonia (VAP) and ventilator associated tracheal (VAT) bronchitis
CN103702663A (zh) 2011-07-12 2014-04-02 卡迪斯制药公司 治疗呼吸机相关肺炎(vap)和呼吸机相关气管(vat)支气管炎的阿米卡星和磷霉素组合的制剂以及方法和系统
PT2567691E (pt) * 2011-09-12 2015-04-09 Pari Pharma Gmbh Composições aquosas que compreendem arbecacina
WO2015031405A1 (en) * 2013-08-26 2015-03-05 Cardeas Pharma Corporation Formulations of aminoglycosides and fosfomycin in a combination having improved chemical properties
EP3219305A1 (de) 2016-03-16 2017-09-20 Apostolos Georgopoulos Fosfomycin-formulierung zur parenteralen verabreichung
WO2024086892A1 (en) * 2022-10-26 2024-05-02 The George Institute for Global Health Stable api formulations comprising micronized tobramycin

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5750919A (en) 1980-09-16 1982-03-25 Meiji Seika Kaisha Ltd Agent for reducing side effect
JPS58134028A (ja) 1982-02-05 1983-08-10 Meiji Seika Kaisha Ltd アミノ配糖体抗生物質腎毒性の軽減乃至予防剤
GB9103291D0 (en) * 1991-02-15 1991-04-03 Waverley Pharma Ltd Transfer adaptor
US5488038A (en) * 1992-11-27 1996-01-30 Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai Dibekacin derivatives and arbekacin derivatives active against resistant bacteria
US5508269A (en) * 1994-10-19 1996-04-16 Pathogenesis Corporation Aminoglycoside formulation for aerosolization
JPH09183730A (ja) 1995-05-10 1997-07-15 Meiji Seika Kaisha Ltd ホスホマイシン鏡像異性体を含んでなる医薬
US6083922A (en) * 1996-04-02 2000-07-04 Pathogenesis, Corp. Method and a tobramycin aerosol formulation for treatment prevention and containment of tuberculosis
US20020017295A1 (en) * 2000-07-07 2002-02-14 Weers Jeffry G. Phospholipid-based powders for inhalation
EP1033133A4 (en) * 1997-10-03 2004-09-01 Meiji Seika Kaisha COMPOSITION FOR TREATING DIABETES AND METHOD FOR TREATING DIABETES
PL348812A1 (en) * 1998-12-17 2002-06-17 Pathogenesis Corp Method for the treatment of severe chronic bronchitis (bronchiectasis) with an aerosolized antibiotic
US20020061281A1 (en) * 1999-07-06 2002-05-23 Osbakken Robert S. Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis
NZ523693A (en) 2000-07-10 2004-08-27 Chiron Corp Macrolide formulations for inhalation and methods of treatment of endobronchial infections
WO2002074247A2 (en) 2001-03-19 2002-09-26 Praecis Pharmaceuticals Incorporated Pharmaceutical formulations for sustained release
PT1320355E (pt) * 2001-05-18 2006-08-31 Chiron Corp Sistema para administracao de uma formulacao de tobramicina
ES2222294T3 (es) * 2001-07-02 2005-02-01 Chiesi Farmaceutici S.P.A. Formulacion optimizada de tobramicina para administracion en forma de aerosol.
JP2005508220A (ja) * 2001-10-24 2005-03-31 パーリ・ゲーエムベーハー 薬用組成物調製用具
TW200403072A (en) * 2002-01-23 2004-03-01 Upjohn Co Combination therapy for the treatment of bacterial infections
US7452524B2 (en) * 2004-01-27 2008-11-18 Gilead Sciences, Inc. Method for improvement of tolerance for therapeutically effective agents delivered by inhalation
EP2316419B1 (en) 2004-05-17 2012-07-11 Gilead Sciences, Inc. Aerosolized fosfomycin/tobramycin combination for the treatment of bacterial respiratory infections
US7838532B2 (en) 2005-05-18 2010-11-23 Mpex Pharmaceuticals, Inc. Aerosolized fluoroquinolones and uses thereof
HUE029994T2 (en) 2005-12-08 2017-04-28 Insmed Inc Lipid-based compositions of antiinfectives for treating pulmonary infections
EP2101787B1 (en) 2006-12-11 2013-09-18 Drugrecure ApS Methods for treating cystic fibrosis or pneumonia with bacterial infection via pulmonary administration of fosfomycin
CA2678587A1 (en) 2007-02-28 2008-09-04 Paringenix, Inc. O-desulfated heparins treating acute exacerbations of chronic obstructive pulmonary disease
WO2010048564A1 (en) 2008-10-23 2010-04-29 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
EP2349263B1 (en) 2008-10-23 2014-04-23 Vertex Pharmaceuticals Inc. Modulators of cystic fibrosis transmembrane conductance regulator
EP2504013A1 (en) 2009-11-24 2012-10-03 Gilead Sciences, Inc. Inhaled fosfomycin/tobramycin for the treatment of chronic obstructive pulmonary disease

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3741866A1 (en) * 2019-05-20 2020-11-25 Liofilchem S.r.l. Kit and method for antibiotics susceptibility testing with the agar dilution method

Also Published As

Publication number Publication date
SI2266534T1 (sl) 2012-12-31
PT2266534E (pt) 2012-10-09
EP2266534B1 (en) 2012-09-26
IL225529A (en) 2014-08-31
EP1750667A4 (en) 2007-07-11
AU2005244153A1 (en) 2005-11-24
US20110117030A1 (en) 2011-05-19
CA2564546A1 (en) 2005-11-24
HK1151191A1 (en) 2012-01-27
AU2009243536B2 (en) 2012-03-22
JP4745340B2 (ja) 2011-08-10
WO2005110022A3 (en) 2006-04-06
DK2316419T3 (da) 2012-10-22
CY1113319T1 (el) 2016-04-13
DK2266534T3 (da) 2013-01-14
EP2316419A1 (en) 2011-05-04
IL179277A0 (en) 2007-05-15
AU2005244153B2 (en) 2009-10-29
HK1157637A1 (en) 2012-07-06
EP1750667B1 (en) 2011-01-05
PL2316419T3 (pl) 2012-12-31
ES2388420T3 (es) 2012-10-15
DK1750667T3 (da) 2011-04-26
AU2009243536A1 (en) 2009-12-24
US20110189103A1 (en) 2011-08-04
DE602005025754D1 (de) 2011-02-17
IL225529A0 (en) 2013-06-27
PT1750667E (pt) 2011-03-11
SI2316419T1 (sl) 2012-10-30
PT2316419E (pt) 2012-10-22
ES2392389T3 (es) 2012-12-10
US8409549B2 (en) 2013-04-02
PL2266534T3 (pl) 2013-02-28
TWI409074B (zh) 2013-09-21
US20130071442A1 (en) 2013-03-21
IL179277A (en) 2013-04-30
US7943118B2 (en) 2011-05-17
CY1112004T1 (el) 2015-11-04
SI1750667T1 (sl) 2011-04-29
ATE493969T1 (de) 2011-01-15
CY1113283T1 (el) 2016-04-13
US8361444B2 (en) 2013-01-29
EP1750667A2 (en) 2007-02-14
JP2007538075A (ja) 2007-12-27
ES2358024T3 (es) 2011-05-04
CA2564546C (en) 2013-02-26
PL1750667T3 (pl) 2011-06-30
US20070218013A1 (en) 2007-09-20
US8980226B2 (en) 2015-03-17
EP2316419B1 (en) 2012-07-11
TW200608983A (en) 2006-03-16
EP2266534A1 (en) 2010-12-29
AR048793A1 (es) 2006-05-24
WO2005110022A2 (en) 2005-11-24

Similar Documents

Publication Publication Date Title
BRPI0509026A (pt) formulação de aerossol, método para a prevenção e tratamento de infecção causada por bactéria do trato respiratório, e, solução
WO2006102345A3 (en) Methods and systems for operating an aerosol generator
WO2007067520A3 (en) Lipid-based compositions of antiinfectives for treating pulmonary infections
TW329387B (en) Pharmaceutical composition for treating airway passage and lung diseases comprising mometasone furoate
BRPI0602430A (pt) composição medicinal, inalador para composição medicinal, método de tratamento de um mamìfero, recipiente do tipo capaz de conter a pressão de vapor de um propelente contido em seu interior e adicionalmente contendo uma composição medicinal adequada para administração a um mamìfero, método de produzir uma formulação aerossol adequada para transferência aos pulmões de um mamìfero por inalação
MX2010002498A (es) Metodos para tratar o prevenir la infeccion del tracto respiratorio que comprende la administracion de colecalciferol.
BRPI0607574A2 (pt) composição farmacêutica aerossol
SE9802073D0 (sv) New use
MY159377A (en) Aqueous suspensions of ciclesonide for nebulisation
WO2005041921A3 (en) Dry powder compositions for inhalation therapy comprising calcium stearate, medical devices therefor
BR0112330A (pt) Formulações de macrolìdeos para inalação e seus usos para o tratamento de infecções endobrÈnquicas
BR0309115A (pt) Composição farmacêutica em pó seco, método de tratamento ou profilaxia de distúrbios respiratórios, uso de uma composição farmacêutica em pó seco, dispositivo de inalação, embalagem de medicamento, e, uso de carboidratos derivados particulados em composição farmacêutica em pó seco
ATE418994T1 (de) Argon enthaltendes arzneimittel zum inhalieren und dessen verwendung zur behandlung von neurotoxizität
SE0950390L (sv) System och process för tillverkning av en lösning med suspenderade fasta ämnen och användningar därför
NO20083683L (no) Nebulisatorformulering
BR0309114A (pt) Uso de carboidratos derivados particulados em composições farmacêuticas em pó seco, composição farmacêutica em pó seco para terapia de inalação, método de tratamento ou profilaxia de distúrbios respiratórios, uso de uma composição farmacêutica em pó seco, dispositivo de inalação, e, embalagem de medicamento
ATE350024T1 (de) Flüssige zubereitung enthaltend tobramycin
NO20054767L (no) Sammensetninger omfattende apomorfin for inhalering i lunge
EP2253312A3 (de) Verwendung von aus extremophilen Bakterien gewonnenen Osmolyten zur Herstellung von inhalierbaren Arzneimittel zur Prophylaxe und Behandlung pulmonaler und kardiovaskulärer Erkrankungen, sowie eine Osmolyte als Wirkstoffbestandteil enthaltende Inhalationsvorrichtung
MX2020010977A (es) Procedimientos de tratamiento de infecciones fúngicas.
NZ597657A (en) Use sulphur particles less than 300 microns and sodium lignin sulfonate for treating diseases casused by microbial pathogenic infections
CN105902555A (zh) 一种新型洗鼻组合剂及其制备方法
WO2007035879A3 (en) Combination s-nitrosothiol-based pharmaceutical products for restoring normal breathing rhythm
WO2004043486A8 (en) An acqueous pharmaceutical formulation comprising the thrombin inhibitor melagatran and use of the formulation in the manufacture of a medicament for use by nasal administration in treating thromboembolism
PRIGAL et al. Streptomycin blood levels following inhalation of steam generated aerosols

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B11T Dismissal of application maintained [chapter 11.20 patent gazette]